News
8
blog,paged,paged-5,bridge-core-1.0.4,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-18.0.8,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-5.7,vc_responsive

Vaccibody AS announced today the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). Patients will receive...

The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015.   Dr. Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako AS, followed by Ostemeter AS...

  Vaccibody AS is pleased to announce initiation of a new 4 year collaborative research project with the aim to improve animal production and health through development of improved vaccination strategies. The SAPHIR project brings together interdisciplinary expertise from 14 academic institutions, 5 small and medium-sized...

Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody plans to initiate its first clinical trial with a...